Youyin Tang
Overview
Explore the profile of Youyin Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teng F, Tang Y, Lu Z, Chen K, Chen Z
BMC Cancer
. 2024 Sep;
24(1):1192.
PMID: 39333915
Background And Aim: The association between gallstones/cholecystectomy and cancer remains inconclusive in the current literature. This study aimed to explore the causal connections between gallstones/cholecystectomy and cancer risk by utilizing...
2.
Teng F, Tang Y, Lu Z, Chen Z, Guo Q
Biomedicines
. 2024 Jun;
12(6).
PMID: 38927386
: Immune-metabolic interactions may have causal and therapeutic impacts on abdominal aortic aneurysms (AAAs). However, due to the lack of research on the relationship between immune-metabolic interactions and AAAs, further...
3.
Wang L, Tang Y, Wang Y
PLoS One
. 2023 Apr;
18(4):e0284414.
PMID: 37053254
The global incidence of infertility is increasing year by year, and the association between infertility and mental illness has been widely concerned. The aim of this study was to investigate...
4.
Yi M, Peng W, Feng X, Teng F, Tang Y, Kong Q, et al.
Aliment Pharmacol Ther
. 2022 Aug;
56(7):1119-1130.
PMID: 35989292
Background: Nonalcoholic fatty liver disease (NAFLD) has reached pandemic proportions currently and may contribute to multiple extrahepatic outcomes. Aim: To comprehensively summarise evidence of associations between NAFLD and risk of...
5.
Yi M, Feng X, Peng W, Teng F, Tang Y, Chen Z
Eur J Clin Pharmacol
. 2022 Jan;
78(4):647-656.
PMID: 35032181
Background: Previous studies have suggested a chemoprotective effect of aspirin in hepatocellular carcinoma (HCC), but evidence is limited for patients with chronic liver disease (CLD). Thus, we performed a meta-analysis...
6.
Xu H, Zou X, Zhao Y, Zhang T, Tang Y, Zheng A, et al.
Technol Cancer Res Treat
. 2021 Sep;
20:15330338211039125.
PMID: 34499018
This study aimed to explore the ability of texture parameters combining with machine learning methods in distinguishing intrahepatic cholangiocarcinoma (ICCA) and hepatic lymphoma (HL). A total of 28 patients with...
7.
Tang Y, Zhang T, Zhou X, Zhao Y, Xu H, Liu Y, et al.
World J Surg Oncol
. 2021 Aug;
19(1):45.
PMID: 34334138
Background: Intrahepatic cholangiocarcinoma is an aggressive liver carcinoma with increasing incidence and mortality. A good auxiliary prognostic prediction tool is desperately needed for the development of treatment strategies. The purpose...
8.
Tang Y, Zhang T, Zhao Y, Chen Z, Ma X
Int J Med Sci
. 2021 Mar;
18(7):1711-1720.
PMID: 33746587
This study aimed to establish and validate a radiomics nomogram comprised of clinical factors and radiomics signatures to predict prognosis of primary hepatic sarcomatoid carcinoma (PHSC) patients after surgical resection....
9.
Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z
Int J Med Sci
. 2021 Jan;
18(1):187-198.
PMID: 33390787
Clinical characteristics and prognosis among combined hepatocellular carcinoma (HCC) and cholangiocarcinoma (cHCC-CC) with HCC and intrahepatic cholangiocarcinoma (ICC) were inconsistent in previous studies. The aim of this study was to...
10.
miR-590-5p promotes liver cancer growth and chemotherapy resistance through directly targeting FOXO1
Jia G, Tang Y, Deng G, Fang D, Xie J, Yan L, et al.
Am J Transl Res
. 2019 May;
11(4):2181-2193.
PMID: 31105827
miR-590-5p functions as an onco-miR or an anti-onco-miR in various types of cancers. However, the exact role of miR-590-5p in liver cancer remains to be elucidated. In the present study,...